Product Information
COBENFY 125 MG-30 MG CAPSULE is a brand product labeled by E.R. Squibb & Sons, L.L.C., priced at $30.2471 per EA under NDC 00003012560. Its NADAC has been published 67 times since Mar 19, 2025.
Strength
30; 125 mg/1; mg/1
Manufacturer
E.R. Squibb & Sons, L.L.C.NDC
00003012560
Classification
Brand
Dosage Form
CAPSULE, COATED PELLETS
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
TROSPIUM CHLORIDE; XANOMELINEApproval Type
New Drug (NDA)
FDA Application
NDA216158On Market Since
9/27/2024
Pharmacological Classes
Price Statistics
The NADAC for COBENFY 125 MG-30 MG CAPSULE has been published 67 times since Mar 19, 2025, and over the history we have for it it has risen 2.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $30.2471 per EA |
|---|---|
| All-time high | $30.3223 (May 13, 2026) |
| All-time low | $29.6004 (Apr 23, 2025) |
| 52-week high | $30.3223 |
| 52-week low | $29.6161 |
| Median price | $29.6639 |
| Average price | $29.8856 |
| Largest weekly change | +2.0% (Jan 14, 2026) |
| Weeks tracked | 67 |
| Tracking since | Mar 19, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the xanomeline and trospium chloride market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of COBENFY 125 MG-30 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for COBENFY 125 MG-30 MG CAPSULE, manufactured by E.R. Squibb & Sons, L.L.C., is $30.2471 per EA (NDC 00003012560), effective Jun 24, 2026.
How has the price of COBENFY 125 MG-30 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for COBENFY 125 MG-30 MG CAPSULE has risen 2.0%. It has been tracked across 67 weekly CMS publications since Mar 19, 2025.
What are the highest and lowest recorded NADAC prices for COBENFY 125 MG-30 MG CAPSULE?
Since Mar 19, 2025, the NADAC for COBENFY 125 MG-30 MG CAPSULE has ranged from a low of $29.6004 (Apr 23, 2025) to a high of $30.3223 (May 13, 2026), with a median of $29.6639 per EA.
Are there cheaper alternatives to COBENFY 125 MG-30 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of COBENFY 125 MG-30 MG CAPSULE, so no direct lower-cost alternative is listed.
Who manufactures COBENFY 125 MG-30 MG CAPSULE?
COBENFY 125 MG-30 MG CAPSULE (NDC 00003012560) is labeled by E.R. Squibb & Sons, L.L.C., and CMS classifies it as a brand product.
Related Drugs
Same classification